CROSSJECT (XPAR:ALCJ) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALCJ CROSSJECT XPAR:ALCJ
40 GF Score
Price €1.72
GF Value €1.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:ALCJ
40GF Score
CROSSJECT XPAR:ALCJ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CROSSJECT (XPAR:ALCJ) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.72 is trading 42.5% above its estimated GF Value™ of €1.21. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for XPAR:ALCJ:

  • FFO:
  • GF Value™: €1.21 vs. price of €1.72 (42.5% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CROSSJECT Business Description

Other Exchanges 74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
40GF Score

Get the complete analysis for XPAR:ALCJ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.72
Price
€1.21
GF Value